Athena Papas
YOU?
Author Swipe
View article: Validation of Dried Saliva for Molecular Diagnostics
Validation of Dried Saliva for Molecular Diagnostics Open
View article: Plain language summary: treatment of Sjögren’s disease with dazodalibep
Plain language summary: treatment of Sjögren’s disease with dazodalibep Open
What is this summary about?
View article: A One-Pot RT-LAMP Diagnostic Assay for SARS-CoV-2 from Saliva Samples
A One-Pot RT-LAMP Diagnostic Assay for SARS-CoV-2 from Saliva Samples Open
Results of efforts to diagnose infections with SARS-CoV-2 using a sampling method that was less invasive than the nasopharyngeal swab led to the rapid adoption of anterior nasal swabs. Saliva was also shown to have potential as a sample ma…
View article: Salivary Extracellular Vesicle RNA Profiling Reveals Biomarkers for Sjögren’s
Salivary Extracellular Vesicle RNA Profiling Reveals Biomarkers for Sjögren’s Open
Sjögren’s is a chronic autoimmune disease affecting exocrine glands and is subclassified into SSA-positive (SSA+) and SSA-negative (SSA-) subtypes, with a complex diagnostic journey and an average diagnostic delay of almost 4 years. While …
View article: Addressing disparities in oral health access and outcomes for aging adults in the United States
Addressing disparities in oral health access and outcomes for aging adults in the United States Open
Oral health is essential for the overall well-being of aging adults, yet significant disparities persist in the United States, contributing to malnutrition, reduced quality of life, and social isolation. Despite advancements in preventive …
View article: Validation of dried saliva for molecular diagnostics
Validation of dried saliva for molecular diagnostics Open
A pivotal moment for the development of point of care diagnostics for COVID-19 was the validation of sample types that were alternatives to nasopharyngeal secretions. Specifically, anterior nasal fluid and saliva demonstrated a promising c…
View article: A one-pot RT-LAMP diagnostic assay for SARS-CoV-2 from saliva samples
A one-pot RT-LAMP diagnostic assay for SARS-CoV-2 from saliva samples Open
Results of efforts to diagnose infections with SARS-CoV-2 using a sampling method that was less invasive than the nasopharyngeal swab led to the rapid adoption of anterior nasal swabs. Saliva was also shown to have potential as a sample ma…
View article: Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study Open
Objective The objective of this study was to report 52‐week safety and efficacy of ianalumab from phase 2b dose‐finding study in patients with Sjögren's disease (SjD). Methods Patients randomly received (1:1:1:1) ianalumab (5, 50, or 300 m…
View article: Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study Open
View article: CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial Open
View article: The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation Open
View article: Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial Open
View article: Identification of Salivary Metabolic Signatures Associated with Primary Sjögren’s Disease
Identification of Salivary Metabolic Signatures Associated with Primary Sjögren’s Disease Open
Sjögren’s disease (SjD) is the second most prevalent autoimmune disorder that involves chronic inflammation of exocrine glands. Correct diagnosis of primary SjD (pSjD) can span over many years since disease symptoms manifest only in advanc…
View article: Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial Open
View article: Minimizing Complications of Aging That Lead to Dry Mouth and Poor Oral Health
Minimizing Complications of Aging That Lead to Dry Mouth and Poor Oral Health Open
Poor oral health causes severe pain and untreated infections to spread throughout the body. For older adults, the prevalence of root decay exceeds that of any other medical condition. Our research shows tooth loss and edentulousness were a…
View article: Conservative Management of Chronic Suppurative Parotitis in Patients with Sjögren Syndrome: A Case Series
Conservative Management of Chronic Suppurative Parotitis in Patients with Sjögren Syndrome: A Case Series Open
BACKGROUND Parotitis is an inflammation of the parotid gland, which can be caused by factors including infection, radiation, and hyposalivation secondary to systemic conditions, such as Sjögren syndrome, rheumatoid arthritis, or medication…
View article: Repeated delivery of chlorhexidine chips for the treatment of peri‐implantitis: A multicenter, randomized, comparative clinical trial
Repeated delivery of chlorhexidine chips for the treatment of peri‐implantitis: A multicenter, randomized, comparative clinical trial Open
Background Peri‐implantitis is a challenging condition to manage and is frequently treated using non‐surgical debridement. The local delivery of antimicrobial agents has demonstrated benefit in mild to moderate cases of peri‐implantitis. T…
View article: Celecoxib Decreases Gcf Prostaglandin E2 Levels in Chronic Periodontitis Patients
Celecoxib Decreases Gcf Prostaglandin E2 Levels in Chronic Periodontitis Patients Open
Prostaglandin E2 (PGE2) is a key mediator associated with periodontal bone loss. We recently demonstrated (Yen, et al, J Periodontology 79:104, 2008) that adjunctive use of Celecoxib (a COX-2 selective inhibitor) in conjunction with Scalin…
View article: Celecoxib Decreases Gcf Prostaglandin E2 Levels in Chronic Periodontitis Patients
Celecoxib Decreases Gcf Prostaglandin E2 Levels in Chronic Periodontitis Patients Open
Periodontal disease is associated with variable microbial patterns, systemic diseases, local and environmental predisposing factors. Development of periodontal disease was believed to depend on the interaction between the resident oral mic…
View article: Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a chlorhexidine dental coating for the prevention of adult caries
Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a chlorhexidine dental coating for the prevention of adult caries Open
Background Dental caries is one of the primary causes of tooth loss among adults. It is estimated to affect a majority of Americans aged 55 and older, with a disproportionately higher burden in disadvantaged populations. Although a number …
View article: FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN'S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL
FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN'S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL Open
View article: Supplementary Material for: Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome
Supplementary Material for: Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome Open
Purpose: We hypothesized that women with primary (pSS) and secondary Sjögren syndrome (sSS; with systemic lupus erythematosus [SLE] or rheumatoid arthritis [RA]) have meibomian gland dysfunction (MGD). We sought to test our h…
View article: Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome
Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome Open
Purpose: We hypothesized that women with primary (pSS) and secondary Sjögren syndrome (sSS; with systemic lupus erythematosus [SLE] or rheumatoid arthritis [RA]) have meibomian gland dysfunction (MGD). We sought to test our h…
View article: Is there a relationship between periodontal conditions and number of medications among the elderly?
Is there a relationship between periodontal conditions and number of medications among the elderly? Open
CAL seems to be more sensitive to the number of medications taken, when compared to PD. However, it is not possible to discriminate at exactly what number of drug combinations the breakdown in CAL will happen. We need to do further analysi…
View article: Is There a Relationship Between Periodontal Disease and Causes of Death? A Cross Sectional Study
Is There a Relationship Between Periodontal Disease and Causes of Death? A Cross Sectional Study Open
The aim of this study was to evaluate whether there is any correlation between periodontal disease and mortality contributing factors, such as cardiovascular disease and diabetes mellitus in the elderly population. A dental evaluation was …